Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082020 | 0.78 | ACHE (0.35) | — | |
| SCHEMBL5793971 | 0.76 | RHOA (0.32) | PDE10A | |
| SCHEMBL7249060 | 0.76 | RHOA (0.32) | KDM4EALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL14164015 | 0.76 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL5272070 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL4192166 | 0.67 | MAPT (0.52) | KDM4EHTT | |
| SCHEMBL6796757 | 0.65 | ADRA2A (0.35) | KDM4EALDH1A1HPGDHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL27151697 | 0.64 | CYP3A4 (0.47) | KDM4EALDH1A1HSD17B10PDE10A | |
| SCHEMBL6625411 | 0.62 | CLK4 (0.37) | KDM4EALDH1A1HTTHSD17B10 | |
| SCHEMBL21468774 | 0.61 | MAPT (0.35) | KDM4EALDH1A1HPGDHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264437-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists | WYETH | 2006-11-23 | — | — | US | disclosed |
| EP-1537122-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6861427-B2 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists | WYETH (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1392697-B1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | WYETH CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004024734-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1392697-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE | Wyeth (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6599915-B2 | 5HT1A antagonist limit the negative feedback of autoceptors seen with serotonic reuptake inhibitors | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-20020183322-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088130-A1 | AZABICYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-F]QUINOLINE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH | 2002-11-07 | — | — | US | disclosed |
| WO-2002088132-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6458802-B1 | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDER, DIETETICS | WYETH | 2002-10-01 | — | — | US | disclosed |
| WO-2002072587-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | WYETH (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045542-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline | CYP19A1, DDT, DRD2 | KDM4E 1123/4885ALDH1A1 408/4885HPGD 1608/4885 |
| US-20020183322-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists | HTR1B, HTR1A, HTR2C | KDM4E 474/4885ALDH1A1 325/4885HPGD 1164/4885 |
| US-20060264437-A1 | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists | HTR2C, HTR5A, HTR1B | KDM4E 478/4885ALDH1A1 542/4885HPGD 1210/4885 |
| US-20020165245-A1 | ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE | CYP19A1, DBH, DDT | KDM4E 1096/4885ALDH1A1 268/4885HPGD 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.